[177Lu]Lu-DFC413 / Novartis - LARVOL DELTA

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer